Also known as: (R)-N-Methyl-3-phenyl-3-(o-tolyloxy)propan-1-amine
Atomoxetine is a highly selective and potent inhibitor of the pre-synaptic noradrenaline transporter, its presumed mechanism of action, without directly affecting the serotonin or dopamine transporters.
This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:
Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):
Atomoxetine is the active ingredient of these drugs:
Germany
Hong Kong
Spain
Austria Poland Romania
United Kingdom
Australia
Estonia Turkey
Hong Kong
Germany
South Africa
Turkey
South Africa
Austria Netherlands
Romania
Spain
Turkey
South Africa
Poland
South Africa
South Africa
Turkey
South Africa
South Africa
Australia Austria Canada Cyprus Ecuador